A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

NCT ID: NCT05371652 Phase: PHASE3 Status: COMPLETED Enrollment: 241 Completion: 2024-02-06

Conditions

Acute Migraine

Interventions

Rimegepant 75mg Orally Disintegrating Tablets (ODT)

Summary

This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine

Primary Outcome

Treatment Safety Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Source

ClinicalTrials.gov